(InSilico Medicine, Inc.) Clinical trial failure rates for small molecules in oncology exceed 94% for molecules previously tested in animals and the costs to bring a new drug to market exceed $2.5 billion. Advances in deep learning demonstrated superhuman accuracy in many areas and are expected to transform industries. Here for the first time we demonstrate the application of Generative Adversarial Autoencoders (AAEs), a new type of Generative Adversarial Networks (GAN), for generation of molecular fingerprints of molecules that kill cancer cells at specific concentrations.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2iiFaJJ
No comments:
Post a Comment